Fate Therapeutics (FATE) Tops Q4 EPS by 1c
Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.30), $0.01 better than the analyst estimate of ($0.31).
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.
Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.30), $0.01 better than the analyst estimate of ($0.31).
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.